ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2442

[18F]-Fluoride PET/CT Assessment In Patients Responding To The ASAS Criteria For Spondyloarthritis Despite Negative Sacroiliac Joint MRI

Cecile Caoduro1, Orland Angoue2, Hatem Boulahdour2 and Eric Toussirot3, 1Nuclear Medicine, University Hospital, Besançon, France, 2Nuclear medicine, University Hospital, Besançon, France, 3Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MRI and diagnosis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: The ASAS group has defined criteria for the diagnosis of axial or peripheral spondyloarthritis (SpA). Sacroiliac joint MRI is included in these criteria and is a pivotal tool in daily practice to evaluate the patients with suspected early and non radiographic SpA. A substantial proportion of patient responds to the ASAS criteria (i.e. the clinical arm) despite negative MRI. Positron emission tomography/computed tomography (PET/CT) is a new imaging technique of potential interest in inflammatory rheumatic diseases. PET/CT has been rarely evaluated in patients with SpA and mainly used [18 F] fluorodeoxyglucose, a marker of inflammation. [18 F] fluoride is a specific bone tracer that may have potential in SpA imaging, a condition associated with spinal ossifications and sacroiliac ankylosis.

Objectives: to evaluate the clinical utility of [18 F] fluoride PET/CT in patients with negative sacroiliac joint MRI but fulfilling the ASAS criteria for SpA.

Methods: consecutive outpatients seen for inflammatory back pain and responding to the ASAS criteria for SpA were included. Patients were previously evaluated by sacroiliac joint MRI (STIR) which must be normal (no bone marrow edema). Whole body [18 F] PET/CT was performed using a SIEMENS Biograph device. Areas of interest (spine, entheseal structures and sacroiliac joints) were examined on whole body scan for the detection of increased uptake.Increased activity was defined as an activity greater than the activity of an adjacent normal bone. Patients with defined ankylosing spondylitis (AS) and positive sacroiliac joint MRI were used as positive controls.

Results: 10 patients were evaluated (8F, 2 M, mean age : 41.8, symptom duration: 3.2 years, HLA B27 positive 9/10 ; mean BASDAI : 5.6, mean ASDAS: 2.3). 9 responded to axial SpA ASAS criteria and I to peripheral SpA ASAS criteria. They all received or had received NSAIDs. No patients had DMARD or TNF inhibitors. All the patients had normal sacroiliac joint MRI. [18 F] fluoride PET/CT did not show increase activity for any patients. 5 patients with radiographic AS and positive MRI were also evaluated: for 4 patients, active lesions were detected with [18 F] fluoride PET/CT showing increased uptake in the sacroiliac joints, the spine and sternoclavicular joints.

Conclusion: [18 F] fluoride PET/CT does not seem useful in patients with inflammatory back pain, negative MRI and responding to the ASAS criteria. Thus, using this bone tracer, PET/CT does not give additional information relevant for the diagnosis of SpA. Conversely, this imaging technique using [18 F] fluoride may be able to detect active lesions in patients with defined disease and positive MRI. Measurement and quantification of maximal standard uptake value may be useful for improving the sensibility of this imaging modality in the diagnosis of SpA.


Disclosure:

C. Caoduro,
None;

O. Angoue,
None;

H. Boulahdour,
None;

E. Toussirot,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/18f-fluoride-petct-assessment-in-patients-responding-to-the-asas-criteria-for-spondyloarthritis-despite-negative-sacroiliac-joint-mri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology